Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome

Por Schramm, A, Schowe, B, Fielitz, K, Heilmann, M, Martin, M, Marschall, T, Köster, J, Vandesompele, J, Vermeulen, J, de Preter, K, Koster, J, Versteeg, R, Noguera, R, Speleman, F, Rahmann, S, Eggert, A, Morik, K, Schulte, J H
Publicado em 2012

A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies

Por Althoff, K, Beckers, A, Bell, E, Nortmeyer, M, Thor, T, Sprüssel, A, Lindner, S, De Preter, K, Florin, A, Heukamp, L C, Klein-Hitpass, L, Astrahantseff, K, Kumps, C, Speleman, F, Eggert, A, Westermann, F, Schramm, A, Schulte, J H
Publicado no Oncogene (2015)